Article
Medicine, General & Internal
Katarzyna Guziejko, Anna Moniuszko-Malinowska, Piotr Czupryna, Marlena Dubatowka, Magda Lapinska, Andrzej Raczkowski, Pawel Sowa, Lukasz Kiszkiel, Lukasz Minarowski, Marcin Moniuszko, Monika Groth, Karol A. Kaminski
Summary: This study investigated the impact of COVID-19 on pulmonary function tests in patients six months after recovery, and examined whether routine testing should be conducted in post-COVID-19 patients. The results showed that some patients still experienced symptoms such as cough and shortness of breath six months after recovery, and their pulmonary function parameters were decreased compared to those without these symptoms.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Leqing Chen, Feihong Wu, Jia Huang, Jinrong Yang, Wenliang Fan, Zhuang Nie, Hongwei Jiang, Jiazheng Wang, Wenfang Xia, Fan Yang
Summary: The aim of this study was to investigate the predictive values of CT indices on pulmonary diffusion function in COVID-19 patients at 5 months after discharge. The study found that over one-third of patients presented with diffusion dysfunction, and well-aerated lung and mean lung density could serve as predictors.
Article
Pediatrics
Gokcen Kartal Ozturk, Burcin Beken, Sumeyra Dogan, Himmet Haluk Akar
Summary: The study found that some children may experience persistent respiratory symptoms after COVID-19 infection, regardless of disease severity, potentially due to inflammation affecting the peripheral airways.
EUROPEAN JOURNAL OF PEDIATRICS
(2022)
Article
Respiratory System
Arianna Sanna, Daniela Pellegrino, Emanuele Messina, Leonardo Maria Siena, Valentina Baccolini, Letizia D'Antoni, Nicholas Landini, Pia Baiocchi, Paolo Villari, Carlo Catalano, Valeria Panebianco, Paolo Palange
Summary: This study evaluated the incidence and risk factors of Post-COVID-19 Interstitial Lung Disease (PC-ILD) in 100 patients with moderate to critical COVID-19. It found that 8% of patients showed residual radiological and functional signs consistent with PC-ILD at the 15-month follow-up. Aging, severity of COVID-19, and degree of pulmonary involvement during acute infection were identified as significant risk factors for developing PC-ILD.
Review
Pharmacology & Pharmacy
Stefan Lassan, Tomas Tesar, Jana Tisonova, Monika Lassanova
Summary: In recent years, COVID-19 has become the leading cause of morbidity and mortality worldwide. This article provides an overview of Post-COVID-19 pulmonary fibrosis and its potential pharmacological treatment options. Various pharmacotherapeutic approaches, including antifibrotic drugs and corticosteroids, are being investigated. Clinical trials are needed to further understand the heterogeneity of the disease and identify effective treatment options.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Pathology
Alain C. Borczuk
Summary: COVID-19 is an acute respiratory illness that can progress to acute respiratory distress syndrome. While most patients recover completely, some may experience persistent respiratory dysfunction, known as long COVID. The pathogenesis involves immune and cellular disturbances.
Article
Immunology
Hiromu Kehara, Chirantan Mangukia, Gengo Sunagawa, Sebastian A. Iturra, Roh Yanagida, Mohammed Kashem, Yuri Persidsky, Kartik Shenoy, Albert J. Mamary, Nathaniel Marchetti, Francis Cordova, Gerard J. Criner, Yoshiya Toyoda, Norihisa Shigemura
Summary: From January 2021 to April 2022, 20 patients underwent lung transplantation for COVID-related lung failure. Among them, 55% had chronic lung disease before contracting COVID-19, and all required hospitalization for antivirus treatment. Postoperative complications included severe primary graft dysfunction and deep venous thrombosis.
Review
Health Care Sciences & Services
Afroditi K. Boutou, Andreas Asimakos, Eleni Kortianou, Ioannis Vogiatzis, Argyris Tzouvelekis
Summary: The COVID-19 pandemic and ARDS have caused a severe global health crisis, with evidence showing that survivors may develop long-term consequences known as the long-COVID-19 syndrome, which affect multiple organs with a variety of symptoms. Management strategies, including corticosteroids, antifibrotic treatment, and pulmonary rehabilitation, are key in improving outcomes for these patients.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Microbiology
Robbert G. Bentvelsen, Andreas L. E. Van Arkel, Tom A. Rijpstra, Merijn K. M. Kant, Simone Van Der Sar-Van Der Brugge, Daan W. Loth, Peter Van Wijngaarden, Arthur W. F. Du Mee, David C. Y. Yick, Bram M. W. Diederen, Peter C. Wever, Alexander C. A. P. Leenders, Laura Van Dommelen, Klaas H. De Groot, Wouter van den Bijllaardt, Paul E. Verweij
Summary: This study aimed to assess the incidence, risk factors, and clinical outcome of COVID-19-associated pulmonary aspergillosis (CAPA) in critically ill COVID-19 patients. A high incidence of CAPA was found, with significantly increased 30-day mortality, highlighting the need for active surveillance and management strategies in critically ill COVID-19 patients.
Article
Radiology, Nuclear Medicine & Medical Imaging
Maurizio Balbi, Caterina Conti, Gianluca Imeri, Anna Caroli, Alessandra Surace, Andrea Corsi, Elisa Mercanzin, Alberto Arrigoni, Giulia Villa, Fabiano Di Marco, Pietro Andrea Bonaffini, Sandro Sironi
Summary: This study evaluated chest CT and PFT findings in severe COVID-19 patients after discharge, revealing that most survivors still had abnormal CT results about three months post-disease onset, with compromised lung volume correlated with PFT results. A small proportion of patients showed impaired diffusion capacity, possibly indicating pulmonary vasculopathy.
EUROPEAN JOURNAL OF RADIOLOGY
(2021)
Review
Radiology, Nuclear Medicine & Medical Imaging
Jeffrey P. Kanne, Brent P. Little, Jefree J. Schulte, Adina Haramati, Linda B. Haramati
Summary: In the 3rd year of the SARS-CoV-2 pandemic, it has been found that about one-third of patients with moderate-to-severe pneumonia, especially those who required intensive care or mechanical ventilation, have residual abnormalities in their lungs one year after initial presentation. These abnormalities range from parenchymal bands to bronchial dilation to fibrosis. The long-term pulmonary vascular sequelae are not well understood, but there seems to be a persistent increased risk of venothromboembolic events in a small group of patients. The histologic abnormalities associated with SARS-CoV-2 infection are similar to those seen in patients with acute lung injury from other causes.
Review
Medicine, General & Internal
Adam Polkinghorne, James M. Branley
Summary: Early treatment of COVID-19 can prevent hospitalisation and death, and there are several medications available for this purpose, including antiviral drugs, monoclonal antibodies, and immunomodulatory drugs. Australia has approved multiple drugs for early treatment, but clinicians need to stay updated on their indications, contraindications, and efficacy against circulating SARS-CoV-2 variants.
MEDICAL JOURNAL OF AUSTRALIA
(2022)
Review
Gastroenterology & Hepatology
Luca Miele, Cecilia Napodano, Alfredo Cesario, Antonio De Magistris, Krizia Pocino, Umberto Basile, Gian L. Rapaccini, Antonio Gasbarrini, Antonio Grieco
Summary: Metabolic diseases are linked to a higher risk of severe COVID-19, with fatty liver exacerbating hepatic inflammation in the presence of SARS-CoV-2 infection. Intestinal dysbiosis serves as a powerful activator of liver macrophage inflammatory response, playing a key role in MAFLD progression towards liver fibrosis.
LIVER INTERNATIONAL
(2021)
Article
Pediatrics
Leona Knoke, Anne Schlegtendal, Christoph Maier, Lynn Eitner, Thomas Luecke, Folke Brinkmann
Summary: This study aimed to investigate the long-term effects of symptomatic and asymptomatic SARS-CoV-2 infections on pulmonary function in children and adolescents. The results showed that pulmonary function is rarely impaired in this age group after SARS-CoV-2 infection, except for those with severe infection.
FRONTIERS IN PEDIATRICS
(2022)
Review
Cell Biology
Janet Johnston, Delia Dorrian, Dermot Linden, Stefan Cristian Stanel, Pilar Rivera-Ortega, Nazia Chaudhuri
Summary: This review discusses the emerging concern of interstitial lung disease (ILD) as a consequence of SARS-CoV-2 infection. The prevailing radiological pattern observed is organizing pneumonia, with ground-glass opacities and reticulation frequently reported. Longitudinal studies reveal a complex trajectory, with some patients showing improvement in lung function and radiographic abnormalities over time while others display more static fibrotic changes. Age, disease severity, and male sex are emerging as risk factors for residual lung abnormalities. Further research and understanding of the relationship between post-COVID ILD and idiopathic pulmonary fibrosis (IPF) genetics are crucial for guiding clinical decisions and improving outcomes for patients.